OmniAb (OABI) Financials: History & Chart

OmniAb, Inc.(OABI)

Biotechnology · EmeryVille, CA

$4.51-0.41 (-8.33%)

Delayed quote: Oct 6, 2026, 12:35 PM EDT

About OmniAb, Inc.

OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.

EmeryVille, CA

89 employees

www.omniab.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Matthew W. Foehr

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	38.43M	13.41M	14.40M	8.38M	2.24M	3.90M	4.15M	10.80M	4.17M
Cost of Goods Sold	19.01M	610K	6.00M	7.72M	4.68M	262K	0.00	0.00	0.00
Gross Profit	19.42M	12.80M	8.40M	660K	-2.44M	3.63M	4.15M	10.80M	4.17M
Gross Profit Margin	50.5%	95.5%	58.3%	7.9%	-109.2%	93.3%	100.0%	100.0%	100.0%
Total Operating Expenses	67.76M	19.44M	16.30M	16.30M	15.72M	19.85M	23.00M	26.68M	23.94M
Research & Development	43.47M	9.59M	9.60M	13.91M	10.38M	10.86M	12.60M	13.31M	13.32M
Selling, General & Administrative	25.44M	6.65M	6.60M	6.84M	5.35M	7.68M	7.92M	7.36M	7.08M
Operating Income (EBIT)	-48.34M	-6.64M	-7.90M	-15.64M	-18.16M	-16.22M	-18.84M	-15.88M	-19.76M
Operating Margin	-125.8%	-49.5%	-54.9%	-186.7%	-811.3%	-416.2%	-453.6%	-147.0%	-473.7%
Income Before Tax (EBT)	-43.82M	-6.21M	-7.70M	-14.55M	-15.36M	-15.76M	-18.31M	-15.22M	-19.08M
Interest Income	2.32M	434K	200K	1.23M	462K	436K	537K	655K	691K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	4.52M	425K	200K	1.10M	2.80M	463K	538K	657K	683K
Net Income	-44.26M	-5.86M	-7.70M	-14.18M	-16.52M	-15.88M	-18.20M	-13.07M	-16.37M
Income Tax Expense	441K	-353K	0.00	-367K	1.16M	119K	-106K	-2.15M	-2.71M
Net Profit Margin	-115.2%	-43.7%	-53.5%	-169.3%	-738.1%	-407.4%	-438.1%	-121.0%	-392.4%
EBITDA	-25.76M	-2.42M	-1.90M	-7.93M	-13.51M	-11.57M	-14.10M	-8.27M	-14.84M
EBITDA Margin	-67.0%	-18.0%	-13.2%	-94.7%	-603.3%	-296.9%	-339.5%	-76.6%	-355.6%
Depreciation & Amortization	22.58M	4.22M	6.00M	7.71M	4.66M	4.65M	4.74M	7.61M	4.93M
EPS Basic	-0.36	-0.05	-0.06	-0.11	-0.14	-0.15	-0.17	-0.12	-0.16
EPS Diluted	-0.36	-0.05	-0.06	-0.11	-0.14	-0.15	-0.17	-0.12	-0.16
Weighted Average Basic Shares	128.79M	128.79M	128.33M	127.79M	114.73M	106.15M	105.62M	104.80M	102.39M
Weighted Average Diluted Shares	128.79M	128.79M	128.33M	127.79M	114.73M	106.15M	105.62M	104.80M	102.39M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Revenue	18.67M	26.39M	34.16M	59.08M	34.75M	23.27M	18.32M
Cost of Goods Sold	22.06M	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-3.39M	26.39M	34.16M	59.08M	34.75M	23.27M	18.32M
Gross Profit Margin	-18.2%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Total Operating Expenses	68.13M	100.89M	103.58M	85.72M	70.36M	48.89M	31.34M
Research & Development	47.75M	55.11M	56.52M	48.36M	39.23M	24.80M	13.21M
Selling, General & Administrative	29.21M	30.74M	33.31M	24.90M	16.95M	10.22M	8.65M
Operating Income (EBIT)	-71.52M	-74.50M	-69.42M	-26.65M	-35.61M	-25.62M	-13.03M
Operating Margin	-383.1%	-282.3%	-203.2%	-45.1%	-102.5%	-110.1%	-71.1%
Income Before Tax (EBT)	-66.29M	-71.41M	-64.36M	-26.06M	-34.35M	-23.73M	-13.03M
Interest Income	2.66M	3.11M	5.05M	587K	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	7K	5K	N/A
Other Income/Expense	5.22M	3.09M	5.06M	587K	1.26M	1.90M	0.00
Net Income	-64.78M	-62.03M	-50.62M	-22.33M	-27.04M	-17.56M	-13.59M
Income Tax Expense	-1.51M	-9.38M	-13.74M	-3.73M	-7.31M	-6.17M	562K
Net Profit Margin	-347.0%	-235.1%	-148.2%	-37.8%	-77.8%	-75.5%	-74.2%
EBITDA	-49.76M	-50.92M	-49.92M	-8.40M	-19.36M	-13.00M	-2.43M
EBITDA Margin	-266.6%	-192.9%	-146.1%	-14.2%	-55.7%	-55.9%	-13.3%
Depreciation & Amortization	21.75M	23.58M	19.50M	18.25M	16.25M	12.63M	10.59M
EPS Basic	-0.57	-0.61	-0.51	-0.26	-0.24	-0.15	-0.12
EPS Diluted	-0.57	-0.61	-0.51	-0.26	-0.24	-0.15	-0.12
Weighted Average Basic Shares	113.64M	102.36M	99.68M	85.32M	114.82M	114.82M	114.82M
Weighted Average Diluted Shares	113.64M	102.36M	99.68M	85.32M	114.82M	114.82M	114.82M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.